Exagen's Q2 2026: Revenue Rises, Loss Narrows, and the ASP Train Keeps Rolling for XGN

Exagen Inc. (Nasdaq: XGN) reported its second quarter 2026 results from Carlsbad, California, highlighting record test volume and a rising trailing twelve-month ASP. The press release flags a narrower net loss and a small adjusted EBITDA loss, while lifting the full-year revenue forecast to a $72–$75 million range. For readers piling into the stock on the back of an EPS discussion, the excerpt does not publish an explicit earnings-per-share figure, but it does set up a framework where markets will watch whether this quarter marks a genuine earnings surprise against the EPS consensus and whether the revenue forecast proves durable into the back half of the year.

Key numbers at a glance

Ticker: XGN; revenue forecast raised to $72–$75 million for 2026.
Three months ended June 30, 2026 revenue: $19.941 million (unaudited).
Six months ended June 30, 2026 revenue: $37.247 million.
Gross margin: 61.3% for the quarter; 60.4% for the first six months of 2026 (versus prior-year comparatives shown in the table).
Profitability touchpoints: net loss reduced by about 30% and adjusted EBITDA loss narrowed to $0.1 million.
Operational signal: management cites record revenue tests and an increase in trailing twelve-month ASP, underscoring pricing power alongside demand growth.
Notes: the table is unaudited and numbers are in thousands, except ASP data.

What this might portend for Exagen and peers

The headline is simple: more revenue, steadier margins, and a clearer path to a smaller loss. But the humility is in the read—Exagen isn’t declaring a victory lap; it’s pricing in a pragmatic narrative: test volume higher, ASP holding up, and costs being managed enough to shrink the red ink modestly. In the linguistics of earnings reporting, that combination often teases at an earnings surprise potential if investors assume the company can translate mid-year momentum into sustainable quarterly EPS improvements.

The 61.3% gross margin is a reassuring sign for a small-cap healthcare company that’s not simply chasing growth by burning cash. Maintaining a gross margin above 60% as revenue steps up suggests favorable mix and some operating leverage—precisely the kind of durability investors crave when evaluating a provider of autoimmune testing solutions whose demand is anchored in payer coverage and clinical adoption, rather than one-off product cycles.

The raised revenue forecast—moving up the full-year trajectory to the low-to-mid $70s in millions—positions Exagen as a steadier grower rather than a confirm-and-reheat story. Yet the stock’s ultimate trajectory will hinge on whether the Q3 and Q4 cadence can sustain, or extend, the current momentum and whether the company can translate this into a meaningful EPS tailwind. The absence of a disclosed EPS figure in the excerpt invites scrutiny: investors may weigh whether the improved EBITDA metric is a harbinger of real cash-flow breathing room or a prelude to further expense discipline that could temper long-range top-line ambitions.

For sector peers, this quarter reinforces a broader narrative: the autoimmune testing space remains attractive when a company can combine test-volume growth with stable pricing. If Exagen can keep ASP momentum intact while managing spend, it may press peers to defend gross margins in a competitive environment where the revenue forecast looks increasingly tied to an ongoing recovery in test volumes rather than one-off product launches.

Bottom line for investors

Exagen’s Q2 2026 results read like a cautious win: revenue growth and volume up, margins sticky above 60%, and losses trimming as management guides toward a full-year revenue target that implies continued momentum into the second half. The real test will be whether the company can sustain this cadence and convert the improved EBITDA signal into a tangible EPS uplift or at least a durable path toward cash profitability. For the sector, the message is clear: the autoimmune testing market can sustain revenue forecasts if test volume and ASP remain aligned, a dynamic that could recalibrate how investors evaluate other small-cap players in this space.

Notes for readers

All figures in this article reflect the press release’s unaudited table and are presented in thousands, except for ASP data. The release notes an increase in trailing twelve-month ASP and mentions “record total revenue, test volume and trailing twelve-month ASP,” signaling a quality-of-growth narrative that investors will parse against upcoming quarterly results and any further refinements to the revenue forecast.